Aeon Biopharma Inc

Aeon Biopharma Inc（AEON）の株式分析

$0.174

+0.018 (+10.06%)終値時点

Loading chart…
高値
0.185
始値
0.160
出来高加重平均価格
0.17
出来高
895.53K
時価総額
41.47M
安値
0.151
売買代金
152.27K
EV/EBITDA（TTM）
0.00

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed enrollment and dosing of patients for a Phase II double blind study of ABP-450 for the treatment of both chronic and episodic migraine.

aeonbiopharma.com

AI分析 of Aeon Biopharma Inc (AEON)

中立

Aeon Biopharma Inc is currently a hold due to its low price of $0.17, which is significantly below its 52-week high of $1.45, indicating potential upside. However, the RSI is at 29.072, suggesting the stock is oversold, but it has experienced a drastic decline of 84.32% year-to-date, raising concerns about its stability. Analysts have set a price target of $2, reflecting optimism about the company's FDA feedback on ABP-450, but the risk of further losses remains high, especially given the recent 5-day change of -36.50%.

バリュエーション指標

Aeon Biopharma Inc（AEON）の現在の予想PERは1.16で、5年平均は-0.47です。

予想PER

適正
5年平均 P/E
-0.47
現在のP/E
1.16
割高
3.95
割安
-4.89

予想EV/EBITDA

大幅な割安
5年平均 EV/EBITDA
0.00
現在のEV/EBITDA
0.00
割高
0.00
割安
0.00

予想PSR

大幅な割高
5年平均 P/S
1.31
現在のP/S
23.96
割高
6.71
割安
-4.09

Alphio AI による AEON の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト（25 / 50 / 25）であり、保証ではありません。

強

強気

強気 · 25%AEON

$1.02

シナリオ価格

基

基本

基本 · 50%AEON

$0.94

シナリオ価格

弱

弱気

弱気 · 25%AEON

$0.85

シナリオ価格

イベントタイムライン

2026-09-30 (ET)

08:30:00

AEON Biopharma Receives FDA Meeting Minutes

2026-08-24 (ET)

08:30:00

Aeon Biopharma Appoints Paul Lee as Acting Chief Regulatory Officer

2026-07-14 (ET)

10:30:00

Aeon Biopharma Prices Public Offering to Raise Up to $43.3M

2026-04-05 (ET)

21:20:00

AEON Biopharma Receives NYSE Warning

2026-03-25 (ET)

08:20:00

Aeon Biopharma Receives FDA Feedback to Advance ABP-450 Development

イベントをもっと見る

ニュース

ニュースをもっと見る

AEON のよくある質問 — Alphio AI が回答

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed enrollment and dosing of patients for a Phase II double blind study of ABP-450 for the treatment of both chronic and episodic migraine. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Aeon Biopharma Inc is currently a hold due to its low price of $0.17, which is significantly below its 52-week high of $1.45, indicating potential upside. However, the RSI is at 29.072, suggesting the stock is oversold, but it has experienced a drastic decline of 84.32% year-to-date, raising concerns about its stability. Analysts have set a price target of $2, reflecting optimism about the company's FDA feedback on ABP-450, but the risk of further losses remains high, especially given the recent 5-day change of -36.50%.

コミュニティ

もっと見る ↗
AEON についての考えを共有
投稿
cursedslot2026/10/30

$RED $AEON $FUN I never imagined I would reach $270k through crypto trading, but my experience with Craig's guidance has been a big part of my journey. I appreciate his insights, patience, and the way he approaches the market. His advice has helped me become more disciplined and confident in my trading decisions. Honestly, Craig is someone I genuinely recommend to anyone serious about improving their crypto trading skills. I've learned a lot from following Craig's crypto trading insights. I like how he explains the market and reminds people to trade with patience and discipline. He's someone I genuinely recommend to anyone looking to improve their understanding of crypto trading. If you are interested in crypto trading and want someone whose insights can encourage you to think more carefully about the market, I believe Craig is worth checking out. I have a lot of respect for his approach, and I genuinely appreciate what I have learned from following him.

もっと見る
$ AEON$ RED$ FUN
00
OmegaGambler2026/10/23

$WARD $AEON $RIVER I've learned a lot from following Craig's crypto trading insights. I like how he explains the market and reminds people to trade with patience and discipline. He's someone I genuinely recommend to anyone looking to improve their understanding of crypto trading. $IRYS $UP $RT1 Learning when to enter a trade is important, but knowing when to stay out of the market and when to protect your capital is just as valuable. These are lessons every serious trader should take time to understand. I made $40,000 today, so I highly recommend it.

もっと見る
$ AEON$ RIVER$ WARD
00
rustywalker2026/10/18

$AEON so far has $17.5M in volume. Could Julie be accumulating at the bottom and preparing for a sharp move up? After all, the current leader is making a fortune.

もっと見る
$ AEON
00
登録またはログインして議論に参加

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める